Dec 10th, 2017 - A second PARP inhibitor shows promise in germline mutation metastatic breast cancer and is generally well tolerated compared with standard chemotherapy.
Feb 9th, 2018 - THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.
Dec 11th, 2017 - Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings.
Dec 17th, 2017 - Breast pain is not often a symptom of breast cancer regardless of age, and mostly women need to be reassured that breast pain is both common and benign.
Feb 9th, 2018 - OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or older enrolled in registration trials of these agents.
Dec 7th, 2017 - Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts
Dec 5th, 2017 - Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.
Jan 1st, 2018 - Enzalutamide added to exemestane improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer, investigators reported
Dec 25th, 2017 - Among patients receiving trastuzumab plus lapatinib neoadjuvant therapy for HER2-positive early breast cancer, amplification of ERBB2 was predictive of a pathologic complete response (pCR), according to findings presented at the San Antonio Breast Cancer Symposium.
Dec 7th, 2017 - The addition of enzalutamide to exemestane significantly prolonged PFS and appeared well tolerated among patients with hormone receptor-positive metastatic breast cancer who had not received prior endocrine therapy and who expressed an androgen receptor gene signature, according to results of a placebo-controlled randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.
Dec 24th, 2017 - An additional 5 years of aromatase inhibitor therapy after 5 years of adjuvant endocrine therapy failed to improve disease-free survival compared with an additional 2 years of aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive breast cancer, according to the results of the large Austrian Breast and Colorectal Cancer Study Group (ABCSG)-16 trial presented at the 2...
Dec 7th, 2017 - Fulvestrant + anastrozole has been shown to improve long-term progression-free and overall survival vs anastrozole alone in women with postmenopausal metastatic breast cancer, despite the use of fulvestrant at a lower dose than approved, and despite substantial crossover to fulvestrant after progression with anastrozole alone.
Dec 7th, 2017 - Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.
Dec 26th, 2017 - Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating HER2+ breast cancer.
Dec 17th, 2017 - Undergoing axillary lymph node dissection (ALND) is more likely to result in arm swelling and decreased range of arm motion in young breast cancer patients, as compared with having a sentinel lymph node biopsy (SLNB), according to new findings.
Dec 10th, 2017 - Women who lose just 5% of their body weight after the menopause may experience a significant reduction in their risk of developing breast cancer vs women with stable weight, say US researchers.
Dec 10th, 2017 - This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.
Dec 6th, 2017 - Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, ...
Dec 24th, 2017 - PREMENOPAUSAL WOMEN with hormone receptor–positive, HER2-negative advanced breast cancer benefited substantially from the addition of ribociclib (Kisqali) to first-line endocrine therapy plus medical ovarian suppression, according to results from the MONALEESA-7 study.
Dec 7th, 2017 - Although a minority of patients with invasive breast cancer expressed microsatellite instability, high tumor mutational load or PD-L1 expression, these biomarkers may elucidate the benefit of immune checkpoint inhibitors for the disease, according to results of a retrospective data analysis presented at the San Antonio Breast Cancer Symposium.